Navigation Links
A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
Date:8/30/2007

lia, is developing a range of therapeutics across the fields of oncology, cardiovascular disease and inflammatory diseases. More information on phenoxodiol and on the Novogen group of companies can be found at http://www.marshalledwardsinc.com and http://www.novogen.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; change
'/>"/>

SOURCE Marshall Edwards Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)... critical enzyme,s regulation may hold key to unde...s , , MEMPHIS, Tenn., Nov. 19 /PRNewswire-U...esearch Hospital have gained new insights into reg...led calpains. , , As the cell,s molecular ...processes, including the movement of cells in tiss...
(Date:11/18/2008)..., make a donation or send a Christmas Seals e-card...wire/ -- Millions will receive Christmas Seals in ... Association. These decorative holiday stamps are ...k to 1907 when the Lung Association led efforts to...s alive today have no vivid memories of how widesp...
(Date:11/13/2008)...tCall/ -- Hologic, Inc.,(Nasdaq: HOLX ), a leadin...diagnostics, medical imaging systems and surgical ... of women, today announced the results of the,Cerv...vista HPV high-risk,test is currently under review...ched in the European Union (EU) early in 2009. The...
(Date:11/12/2008)...r 12 Surgeons,at the University of...nt-specific CTA data can be converted to an endova...with high face validity. The surgeons,"strongly ag...low,increased patient safety and efficiency of in...roscopy time and the amount of contrast used, and,...
Breaking Medicine Technology:New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 3Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 4Vascular Surgeons Agree: Case Rehearsal Improves Outcomes 2Researchers discover cells quality control mechanism 4249 1Researchers discover cells quality control mechanism 4249 2South African Farmers Increase Plantings of Genetically Modified Crops 6799 1South African Farmers Increase Plantings of Genetically Modified Crops 6799 2South African Farmers Increase Plantings of Genetically Modified Crops 6799 3Huifeng Bio Pharmaceutical 28HFGB 29 Provides Update on COS Application Status 6798 1Huifeng Bio Pharmaceutical 28HFGB 29 Provides Update on COS Application Status 6798 2Huifeng Bio Pharmaceutical 28HFGB 29 Provides Update on COS Application Status 6798 3Killer pulses help characterize special surfaces 4246 1Killer pulses help characterize special surfaces 4246 2
(Date:11/21/2008)...ective against Lennox-Gastaut syndrome , ...called Banzel (rufinamide) has been approved as a ...psy called Lennox-Gastaut syndrome, the U.S. Food ... approval was based on results of a four-month cli...ompared to patients who took a placebo, those who ...
(Date:11/21/2008)...re/ -- NursingCenter.com, the premier site,for on...d content, has been,updated to improve the intera.... Powered by Lippincott Williams & Wilkins (LW...reviewed continuing education activities and free,...ng nursing journals.,Lippincott Williams & Wi...
(Date:11/21/2008)...PRNewswire-FirstCall/ -- Today, prescription drugs...treating 88 percent of patients suffering chronic ...or a chronic condition account for 96 percent of a...l medical costs. A proprietary new pharmacy model...ons, Inc. (NYSE: MHS ) significantly reduces cri...
(Date:11/21/2008)... diseaseits cause remains a mysteryswept into Athe...itizens, soldiers and refugees of the war then rag...ith corpses, social order broke down. Over the nex...ns lost a third of its population. It lost the war... the end of the Golden Age of Greece. , The Pla...
Breaking Medicine News(10 mins):Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4
...atest study researchers have observed that doctors...ood pressure and other cardiac risk factors in eth...tal, Georgia have carried out a population survey ...igins, looking at their heart disease and stroke r...
...of a patient can have a major impact on how suscep...id arthritis, according to new research. The publi...to factors// not related to the disease when they ...oubt being diagnosed with a chronic, disabling dis...
... alfa treats anaemia in cancer patients and thereb...ry common side effect of cancer chemotherapy. It r... the protein that carries oxygen round the body. T...lming exhaustion that is not relieved by rest. Pat...
...rve that a new topical medication can effectively ...he sun. They found that in a long-term study of ta...nkling and mottled skin in more than 55 percent// ...how additional benefit as the length of use increa...
Other Medicine News:Health News:Personality Impacts Arthritis 2
...ormance Tecoflex stents that save inventory, shelf...eteral Stents accommodate ureteral lengths from 22...ws the Quadra-Coil to glide over any guidewire and...provide ease of placement and patient comfort in a...
...temporary internal drainage from the ureteropelvic...is engineered for ease of placement and patient co... designed for repositioning and ease of removal. A... that when activated, attracts and holds water and...
The CMV IgM enzyme immunoassay is for the qualitative detection of antibodies to cytomegalovirus. The CMV IgM assay is primarily indicated for the detection of early or recent infection.
The Shandon Sequenza uses the Shandon Coverplate system which ensures consistency and excellent staining quality. , , ,Allows the user to perform large immunostaining runs (up to 50 slides/run
Medicine Products: